

IN THE CLAIMS:

Claim 1. (Currently Amended) A pharmaceutical composition comprising a neuroprotective amount of pGLU-GLU-PRO-amide as an active ingredient and a pharmaceutically acceptable carrier, wherein said neuroprotective amount is an amount ~~suffieient~~ of about 4.0 to about 10 mg/kg to reduce Glu induced neurotoxicity in brain, spinal cord and/or retina.

Claim 2. (canceled)

Claim 3. (Previously Amended) A pharmaceutical composition comprising pGLU-GLU-PRO-NH₂ and N-tert-Butyl- α -(2-sulfophenyl)nitron as active ingredients.

Claim 4. (canceled)

Claim 5. (previously amended) A pharmaceutical composition comprising pGLU-GLU-PRO-NH₂ and one or more nitrones as active ingredients.

Claim 6. (canceled)

Claim 7. (previously amended) A method of reducing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a patient a composition comprising a therapeutically effective amount of pGLU-GLU-PRO-NH₂ as an active ingredient under time and conditions to treat said Glu induced neurotoxicity.

Claim 8. (original) The method of claim 7, wherein said administering comprises administering to said patient the composition via oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, intrathecal, rectal or intranasal routes.

Claim 9. (canceled)

Claim 10. (Previously Amended) A method of reducing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a patient a composition comprising a therapeutically effective amount of (a) pGLU-GLU-PRO-NH₂ and (b) N-tert-Butyl- α -(2-sulfophenyl) nitron or a free radical scavenging nitron that enhances the effects of pGLU-GLU-PRO-NH₂ under time and conditions to treat said Glu induced neurotoxicity.

Claim 11. (original) The method of claim 10, wherein said administering comprises administering to said patient the composition via oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, intrathecal, rectal or intranasal routes.

Claim 12. (canceled)

Claim 13. (currently amended) A method of preventing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a ~~patient~~ patient a composition comprising a therapeutically effective amount of pGLU-GLU-PRO-NH₂ as an active ingredient under time and conditions to treat said Glu induced neurotoxicity.

Claim 14. (canceled)

Claim 15. (previously added) The composition of claim 1, wherein said pharmaceutically acceptable carrier is one or more ingredients selected from the group consisting of: starch, sugar, flavoring agents, preservatives, water, organic co-solvents, flavor emulsions, oils and elixirs.

Claim 16. (previously added) The composition of claim 1, wherein said pharmaceutically acceptable carrier affords prolonged action or sustained release.